抗肿瘤药马赛替尼在治疗神经退行性疾病中的研究进展  

Research progress of masitinib,an antitumor drug in the treatment of neurodegenerative diseases

作　　者：沈千惠 贾康 刘源 张志先 麦成雄 皮荣标 周四桂 SHEN Qianhui;JIA Kang;LIU Yuan;ZHANG Zhixian;MAI Chengxiong;PI Rongbiao;ZHOU Sigui(School of Pharmacy,Guangdong Pharmaceutical University,Guangzhou 510006,China;School of Medicine,Sun Yat-sen University,Shenzhen 518107,China;Department of Food and Health Science,Technological and Higher Education Institute of Hong Kong,Hong Kong 999077,China)

机构地区：[1]广东药科大学药学院,广东广州510006 [2]中山大学医学院,广东深圳518107 [3]香港高等教育科技学院食品及健康科学学系,中国香港999077

出　　处：《药学研究》2025年第3期257-264,共8页Journal of Pharmaceutical Research

基　　金：国家自然科学基金项目(No.81671264)。

摘　　要：阿尔茨海默病(Alzheimer′s disease,AD)、肌萎缩侧索硬化症(amyotrophic lateral sclerosis,ALS)和多发性硬化症(multiple sclerosis,MS)等神经退行性疾病患病人数逐年增加,但仍缺乏确凿有效的治疗药物。马赛替尼最初作为一种口服多靶点酪氨酸激酶抑制剂用于治疗癌症,近来研究发现,其对多种神经退行性疾病表现出潜在的神经保护作用。本文综述了马赛替尼在治疗AD、ALS及MS方面的研究进展。The prevalence of neurodegenerative diseases such as Alzheimer's disease(AD),amyotrophic lateral sclerosis(ALS),and multiple sclerosis(MS)is increasing annually,yet effective therapeutic drugs remain elusive.Masitinib,originally developed as a tyrosine kinase inhibitor for cancer treatment,has recently shown potential neuroprotective effects in various neurological disorders.This review summarized the research progress of Masitinib in the treatment of AD,ALS and MS.

关 键 词：马赛替尼 阿尔茨海默病 肌萎缩侧索硬化症 多发性硬化症 

分 类 号：R741[医药卫生—神经病学与精神病学]